Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Shares Outstanding (Diluted Average) (2020 - 2025)

Tg Therapeutics (TGTX) has 4 years of Shares Outstanding (Diluted Average) data on record, last reported at $141.5 million in Q2 2023.

  • For Q2 2023, Shares Outstanding (Diluted Average) rose 4.99% year-over-year to $141.5 million; the TTM value through Jun 2023 reached $141.5 million, up 4.99%, while the annual FY2022 figure was $135.4 million, 2.41% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $141.5 million in Q2 2023 per TGTX's latest filing, up from $140.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $141.5 million in Q2 2023 and bottomed at $115.3 million in Q4 2020.
  • Average Shares Outstanding (Diluted Average) over 4 years is $133.2 million, with a median of $134.4 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 14.64% in 2021, then rose 1.9% in 2022.
  • A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $115.3 million in 2020, then rose by 14.64% to $132.2 million in 2021, then grew by 2.41% to $135.4 million in 2022, then rose by 4.5% to $141.5 million in 2023.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $141.5 million in Q2 2023, $140.3 million in Q1 2023, and $135.4 million in Q4 2022.